Target
ODF, TNF-related activation-induced cytokine, Osteoclast differentiation factor, TNFSF11, TRANCE, Osteoprotegerin ligand, RANKL, Tumor necrosis factor ligand superfamily member 11, Receptor activator of nuclear factor kappa-B ligand, CD254, OPGL
Background
Narlumosbart (JMT103) is an IgG4κ antibody targeting receptor activator of nuclear factor-κB ligand (RANKL).• Biology of the TRANCE axis., PMID:12787563• Regulation of the differentiation and function of osteoclasts., PMID:10951393• The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption., PMID:10646108• Minireview: the OPG/RANKL/RANK system., PMID:11713196• Importance of membrane- or matrix-associated forms of M-CSF and RANKL/ODF in osteoclastogenesis supported by SaOS-4/3 cells expressing recombinant PTH/PTHrP receptors., PMID:10976996• Expression of parathyroid hormone-related protein (PTHrP), osteoclast differentiation factor (ODF)/receptor activator of nuclear factor-kappaB ligand (RANKL) and osteoclastogenesis inhibitory factor (OCIF)/osteoprotegerin (OPG) in ameloblastomas., PMID:14675140• The molecular basis of osteoclast differentiation and activation., PMID:11277084• The role of TNF-receptor family members and other TRAF-dependent receptors in bone resorption., PMID:11178122• Characterization of osteoclast precursors in human blood., PMID:11122091• Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction., PMID:10637272